Abstract:The approval of COVID-19 vaccines and two classes of antiviral drugs has been crucial in addressing the global health crisis caused by SARS-CoV-2. However, to prepare for future outbreaks from drug-resistant variants and novel zoonotic coronaviruses (CoVs), additional therapeutics with a distinct antiviral mechanism are needed. Here, we report a novel guanidine-substituted diphenylurea compound that suppresses CoV replication by interfering with the uridine-specific endoribonuclease (EndoU) activity of the viral non-structural protein-15 (nsp15). This compound, designated EPB-113, exhibits strong and selective cell culture activity against human coronavirus 229E (HCoV-229E) and also suppresses the replication of SARS-CoV-2. HCoV-229E viruses selected for resistance to EPB-113 carried mutations at or near the catalytic residue His250 in the nsp15 EndoU domain. EndoU is known to reduce the levels of viral dsRNA and avoid induction of type I interferon (IFN-I). Accordingly, the mutant viruses selected under EPB-113 were unable to replicate in human macrophages and were readily outcompeted by the wild-type virus upon co-infection of human fibroblast cells. This highlights the critical role of EndoU in maintaining CoV replication. By targeting nsp15, EPB-113 combines a direct antiviral effect with subtle boosting of IFN-I. Using a combination of biophysical and enzymatic assays with the recombinant nsp15 proteins from HCoV-229E and SARS-CoV-2, we discovered that EPB-113 reduces the thermal stability of hexameric nsp15, while enhancing its EndoU cleavage activity. This EndoU-stimulating mechanism offers an explanation why the virus escapes EPB-113 by becoming EndoU-deficient. Our findings suggest that targeting nsp15 as an antiviral strategy may require a mechanism that alters the conformation of this protein and disrupts its EndoU activity and other functions related to immune evasion and viral replication. Based on the appealing pharmacological profile of EPB-113, we conclude that nsp15 is a challenging but highly relevant drug target.

Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia

Plitidepsin as an Immunomodulator against Respiratory Viral Infections

Crystal structure and activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease revealed new allosteric sites for antiviral therapies

Computational Prediction of the Potential Target of SARS‐CoV‐2 Inhibitor Plitidepsin via Molecular Docking, Dynamic Simulations and MM‐PBSA Calculations

Activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease with antiviral efficacy in murine infection model

A Repurposed Drug Interferes with Nucleic Acid to Inhibit the Dual Activities of Coronavirus Nsp13

Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19

Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2

Attacking the SARS-CoV-2 Replication Machinery with the Pathogen Box’s Molecules

The effects of Remdesivir's functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase

Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease

Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity

Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response

Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors

Promising antivirals for PLpro of SARS-CoV-2 using virtual screening, molecular docking, dynamics, and MMPBSA

Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2

Utilization of the EpiMed Coronabank Chemical Collection to identify potential SARS-CoV-2 antivirals: in silico studies targeting the nsp14 ExoN domain and PL pro naphthalene binding site

A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and combines a direct antiviral effect with subtle boosting of interferon

Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases

A pan-respiratory antiviral chemotype targeting a transient host multi-protein complex